Then, to determine if FABP4 and MMP9 mRNA expression levels could be used as prognostic markers in NAFL and/or NASH patients, we analyzed their expression levels in our Validation cohort (Fig. 1) using a ROC curve analysis. Here, FABP4 is linked to metabolic dysfunction-associated steatohepatitis.